Project Grant R01HL173152
Award Date
5/15/25
Completion Date
2/28/29
Dollars Obligated
$761K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will support research to characterize the role of lung stromal factors in modulating the inflammatory response and tissue-resident lymphocyte accumulation in asthmatic airways. The $636,843 award to the Regents of the University of California, San Francisco will utilize novel genetic tools, human organoid platforms, and a proprietary...
This federal Project Grant award, totaling $880,735.00 and issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the mechanisms by which cell lysis and the release of leukotriene C4 (LTC4) and its metabolite LTD4 activate group 2 innate lymphoid cells (ILC2s) and induce type 2 immunity in the lung. The University of Washington is the prime awardee and will investigate how alveolar...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune cell crosstalk and its impact on lung injury, fibrosis, and host defense against infections. The key objectives of this 7-year project are to: 1) study how epithelial cell signaling via heparin-binding EGF-like growth factor (HB-EGF) regulates fibrosis...
This $347,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel, oral, once-daily immunoregulatory therapeutic for the treatment of asthma by Biotherapeutics, Inc., an emerging biotechnology company. The goal is to characterize the therapeutic efficacy and administration route of the drug candidate in mouse models of asthma, and determine its translational potential...
This $775,992 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in resolving acute lung injury and pneumonia. The project aims to determine how Treg glucocorticoid receptor signaling affects Treg function and the...
This federal Project Grant award of $387,116 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to define the neural mechanisms triggered by house dust mite (HDM) exposure that lead to the development of airway hyperreactivity (AHR) in asthma. The research seeks to identify the specific nerve subtypes and signaling pathways involved in HDM-induced AHR, in order to develop targeted therapies. Specifically, the study...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $480,990 to the University of Illinois to investigate the role of aerocytes, a specialized capillary endothelial cell population, in promoting alveolar epithelial regeneration following lung injury. The research aims to establish the central regulatory function of aerocyte-derived signaling, particularly the angiocrine factor...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $715,968 to Brigham & Women's Hospital Inc. to conduct research on the mechanisms underlying mast cell expansion and function in human airway diseases. The key objectives of this 5-year project are to: 1) evaluate the concentration of mast cell progenitors in human sinus tissue across different disease endotypes, 2) test the...
This federal Project Grant award of $1,788,091 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the mechanisms of persistent lung inflammation in cystic fibrosis (CF). The primary awardee, Dartmouth-Hitchcock Clinic, will investigate differences in lung macrophage function, metabolism, and inflammatory response between CF patients, non-CF bronchiectasis patients, and healthy controls. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $615,455 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Tennessee Health Science Center. The award will fund research to investigate the role of eosinophils, a type of white blood cell, in mediating antibacterial immunity against Streptococcus pneumoniae (pneumococcus) in the lungs. The project aims to elucidate the mechanisms by which eosinophils interact with and kill...